Video

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial (NCT03170960), which is enrolling patients with metastatic castration-resistant prostate cancer (mCRPC).

The COSMIC-021 trial is evaluating the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq), which initially launched in a smaller number of malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer, Pal explains. Now, the study has expanded to include additional malignancies, such as lung cancer, hepatocellular carcinoma, and triple-negative breast cancer, among others.

In 2019, results from the renal cell carcinoma cohort were presented, which demonstrated encouraging response rates with the combination. At the 2020 Genitourinary Cancers Symposium, data with the combination showcased its efficacy in patients with mCRPC, including those with high-risk clinical features. Cabozantinib plus atezolizumab elicited an overall response rate (ORR) of 32%, including 2 complete responses and 12 partial responses, in the overall cohort of patients with mCRPC. In those with visceral metastases and/or extra-pelvic lymph node metastases, the ORR was 33%.

These data are serving as the foundation for a phase III trial that is expected to launch soon, Pal concludes.

<<< View more from the 2020 Genitourinary Cancers Symposium

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD